Client : Chine
« Sinovac has received its second purchase order for its H1N1 vaccine, PANFLU.1, from the Ministry of Industry and Information Technology of the People's Republic of China for the national stockpiling plan. Under this purchase order, Sinovac is required to produce an additional 3 million doses of PANFLU.1 (15ug/0.5ml), Sinovac's H1N1 vaccine for the central government.
The 3 million dose purchase order announced today is in addition to the initial order for 3.3 million doses received from the Ministry of Industry and Information Technology of China on September 4, 2009. Sinovac is expected to complete the delivery of 4.5 million doses of PANFLU.1 to the Chinese central government by the end of October.
To date, more than 100,000 citizens in Beijing have been inoculated by PANFLU.1, Sinovac's H1N1 vaccine and no severe adverse events have been reported, demonstrating the good safety profile of Sinovac's H1N1 vaccine. In the vaccination campaign initiated in China, the side effects were monitored proactively through adverse events following immunization (AEFI). »
Source : communiqué de presse de Sinovac, 30 septembre 2009.
« Le prix du vaccin sera « d'environ 30 dollars, et nous pouvons le vendre environ 30% moins cher [...] Nous espérons obtenir l'approbation du régulateur chinois durant la première quinzaine de septembre. »
Source : Propos de Weidong Yin, directeur général de Sinovac - 31 août 2009.
>> Informations sur les vaccins contre la grippe A H1N1